Acromegaly Patients adequately controlled w/ SC Sandostatin Initially 20 mg 4 wkly for 3 mth. Start treatment on the day after the last dose of SC Sandostatin. Thereafter, the dose may be increased to 30-40 mg (if still not adequately controlled after 3 mth) 4 wkly, or decreased to 10 mg 4 wkly.
Patients in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective A short test dosing period of SC Sandostatin prior to initiating treatment w/ Sandostatin LAR as described previously.
Gastroenteropancreatic endocrine tumors Patients adequately controlled w/ SC Sandostatin Initially 20 mg 4 wkly. Continue treatment w/ SC Sandostatin at previously effective dosage for 2 wk after the 1st Sandostatin LAR inj.
Patients not previously treated w/ SC Sandostatin Initially 0.1 mg tds of SC Sandostatin for approx 2 wk to assess response & systemic tolerability to octreotide before initiating Sandostatin LAR treatment as described previously. After 3 mth, dose may be reduced to 10 mg 4 wkly, or increased to 30 mg 4 wkly.
Treatment of patients w/ advanced neuroendocrine tumors of midgut or unknown primary tumor location 30 mg 4 wkly. Continue treatment in the absence of tumor progression.
Sign Out
